One of the major problems of modern oncology drug is liver damage, requiring additional costs for its treatment. The aim of our work was to study medical and economic efficiency of various schemes of hepatoprotective treatment of toxic liver damage. The paper presents the use of pharmacoeconomic studies in the treatment of hepatic drug-induced hepatitis, which occurs after chemotherapy in patients with Hodgkin's lymphoma. The study was conducted in the two comparison groups on a "cost - effectiveness". This method was chosen because it is in effect depending on the process (method), treatment was varied, as well as costs incurred. The unit of the effect of the number of days required for the relief of hepatic failure has been selected. Economic analysis of the work includes not only toxic hepatitis therapy, and treatment of any disease complications such as hepatic encephalopathy. The study revealed that the effectiveness of therapy increased 1.4 times and the economic costs were 51.8 % reduced with hepatoprotective drug "remaxol".
展开▼
